Christopher Luckhurst is the Head of Chemistry at ThirtyFiveBio, where they lead the development of novel modulators targeting the GPR35 receptor for treating digestive system cancers. With extensive experience in drug development and medicinal chemistry, Christopher has successfully managed projects from hit finding through preclinical discovery phases, delivering clinical candidates in various therapeutic areas, including neurodegeneration and cardiovascular diseases. They have held leadership roles in established companies like Pfizer, AstraZeneca, and Charles River Laboratories, contributing to over 50 peer-reviewed publications and patents. Christopher earned a PhD in Total Synthesis from the University of Cambridge and holds a First-Class Honours degree in Biochemistry and Biological Chemistry from the University of Nottingham.
This person is not in the org chart
This person is not in any teams
This person is not in any offices